Skip to Content

Generic Kazano Availability

Last updated on July 7, 2021.

Kazano is a brand name of alogliptin/metformin, approved by the FDA in the following formulation(s):

KAZANO (alogliptin benzoate; metformin hydrochloride - tablet;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: January 25, 2013
    Strength(s): EQ 12.5MG BASE;1GM [RLD], EQ 12.5MG BASE;500MG [RLD]

Has a generic version of Kazano been approved?

No. There is currently no therapeutically equivalent version of Kazano available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kazano. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dipeptidyl peptidase inhibitors
    Patent 7,807,689
    Issued: October 5, 2010
    Inventor(s): Zhang; Zhiyuan & Elder; Bruce J. & Isbester; Paul K. & Palmer; Grant J. & Ulysse; Luckner G.
    Assignee(s): Takeda Pharmaceutical Company Limited

    The present invention provides a compound of the formula: or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same.

    Patent expiration dates:

    • June 27, 2028
      ✓ 
      Patent use: METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Dipeptidyl peptidase inhibitors
    Patent 8,173,663
    Issued: May 8, 2012
    Inventor(s): Feng; Jun & Gwaltney; Stephen L. & Stafford; Jeffrey A. & Zhang; Zhiyuan & Elder; Bruce J. & Isbester; Paul K. & Palmer; Grant J. & Salsbury; Jonathon S. & Ulysse; Luckner G.
    Assignee(s): Takeda Pharmaceutical Company Limited

    Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising: wherein M is N or CR4; Q1 and Q2 are each independently selected from the group consisting of CO, SO, SO2, and C═NR9; and each L, X, R1, R2, and R3 are as defined herein.

    Patent expiration dates:

    • March 15, 2025
      ✓ 
      Patent use: METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
  • Dipeptidyl peptidase inhibitors
    Patent 8,288,539
    Issued: October 16, 2012
    Inventor(s): Feng; Jun & Gwaltney; Stephen L. & Stafford; Jeffrey A. & Zhang; Zhiyuan & Elder; Bruce J. & Isbester; Paul K. & Palmer; Grant J. & Salsbury; Jonathon S. & Ulysse; Luckner G.
    Assignee(s): Takeda Pharmaceutical Company Limited

    Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising: wherein M is N or CR4; Q1 and Q2 are each independently selected from the group consisting of CO, SO, SO2, and C═NR9; and each L, X, R1, R2, and R3 are as defined herein.

    Patent expiration dates:

    • June 24, 2025
      ✓ 
      Drug substance
  • Solid preparation comprising alogliptin and metformin hydrochloride
    Patent 8,900,638
    Issued: December 2, 2014
    Assignee(s): Takeda Pharmaceutical Company Limited

    The present invention provides a solid preparation containing compound (I) [compound (I) is as defined in the specification] or a salt thereof, and metformin hydrochloride, which is useful as a therapeutic drug for diabetes and the like, and superior in the preservation stability. A solid preparation having a first part and a second part: a first part: a part containing compound (I) or a salt thereof and substantially free of metformin hydrochloride a second part: a part containing metformin hydrochloride and substantially free of compound (I) and a salt thereof.

    Patent expiration dates:

    • May 24, 2029
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.